Skip to main content
NCBI home page
British Heart Journal logoLink to British Heart Journal
. 1978 Oct;40(10):1069–1118. doi: 10.1136/hrt.40.10.1069

A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators.

PMCID: PMC483536  PMID: 361054

Full text

PDF
1069

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BLACKBURN H., KEYS A., SIMONSON E., RAUTAHARJU P., PUNSAR S. The electrocardiogram in population studies. A classification system. Circulation. 1960 Jun;21:1160–1175. doi: 10.1161/01.cir.21.6.1160. [DOI] [PubMed] [Google Scholar]
  2. Barnett D., Craig J. G., Robinson D. S., Rogers M. P. Effect of clofibrate on glucose tolerance in maturity onset diabetes. Br J Clin Pharmacol. 1977 Aug;4(4):455–458. doi: 10.1111/j.1365-2125.1977.tb00761.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Barrett A. M., Thorp J. M. Studies on the mode of action of clofibrate: effects on hormone-induced changes in plasma free fatty acids, cholesterol, phospholipids and total esterified fatty acids in rats and dogs. Br J Pharmacol Chemother. 1968 Feb;32(2):381–391. doi: 10.1111/j.1476-5381.1968.tb00980.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Berkowitz D. Long-term treatment of hyperlipidemic patients with clofibrate. JAMA. 1971 Nov 15;218(7):1002–1005. [PubMed] [Google Scholar]
  5. Brown D. F., Kinch S. H., Doyle J. T. Serum triglycerides in health and in ischemic heart disease. N Engl J Med. 1965 Oct 28;273(18):947–952. doi: 10.1056/NEJM196510282731802. [DOI] [PubMed] [Google Scholar]
  6. Carlson L. A., Böttiger L. E. Ischaemic heart-disease in relation to fasting values of plasma triglycerides and cholesterol. Stockholm prospective study. Lancet. 1972 Apr 22;1(7756):865–868. doi: 10.1016/s0140-6736(72)90738-6. [DOI] [PubMed] [Google Scholar]
  7. Cooper J., Geizerova H., Oliver M. F. Letter: Clofibrate and gallstones. Lancet. 1975 May 10;1(7915):1083–1083. doi: 10.1016/s0140-6736(75)91845-0. [DOI] [PubMed] [Google Scholar]
  8. Dewar H. A., Oliver M. F. Secondary prevention trials using clofibrate: a joint commentary on the Newcastle and Scottish trials. Br Med J. 1971 Dec 25;4(5790):784–786. doi: 10.1136/bmj.4.5790.784. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Einarsson K., Hellström K., Leijd B. Bile acid kinetics and steroid balance during nicotinic acid therapy in patients with hyperlipoproteinemia types II and IV. J Lab Clin Med. 1977 Oct;90(4):613–622. [PubMed] [Google Scholar]
  10. Enger S. C., Johnsen V., Samuelsen A., Laws E. A. The effect of clofibrate on glucose tolerance, insulin secretion, triglycerides and fibrinogen in patients with coronary heart disease. Acta Med Scand. 1977;201(6):563–566. doi: 10.1111/j.0954-6820.1977.tb15748.x. [DOI] [PubMed] [Google Scholar]
  11. Feinstein A. R. Clinical biostatistics. 18. The clofibrate trials: another dispute about contratrophic therapy. Clin Pharmacol Ther. 1972 Nov-Dec;13(6):953–968. doi: 10.1002/cpt1972136953. [DOI] [PubMed] [Google Scholar]
  12. Fredrickson D. S., Levy R. I., Lees R. S. Fat transport in lipoproteins--an integrated approach to mechanisms and disorders. N Engl J Med. 1967 Feb 2;276(5):273–concl. doi: 10.1056/NEJM196702022760507. [DOI] [PubMed] [Google Scholar]
  13. Grundy S. M., Ahrens E. H., Jr, Salen G., Schreibman P. H., Nestel P. J. Mechanisms of action of clofibrate on cholesterol metabolism in patients with hyperlipidemia. J Lipid Res. 1972 Jul;13(4):531–551. [PubMed] [Google Scholar]
  14. Halperin M., Cornfield J., Mitchell S. C. Effect of diet on coronary-heart-disease mortality. Lancet. 1973 Aug 25;2(7826):438–439. doi: 10.1016/s0140-6736(73)92292-7. [DOI] [PubMed] [Google Scholar]
  15. Heady J. A. A cooperative trial on the primary prevention of ischaemic heart disease using clofibrate: design, methods, and progress. Bull World Health Organ. 1973;48(2):243–256. [PMC free article] [PubMed] [Google Scholar]
  16. Hill M. J., Drasar B. S., Williams R. E., Meade T. W., Cox A. G., Simpson J. E., Morson B. C. Faecal bile-acids and clostridia in patients with cancer of the large bowel. Lancet. 1975 Mar 8;1(7906):535–539. doi: 10.1016/s0140-6736(75)91556-1. [DOI] [PubMed] [Google Scholar]
  17. KANNEL W. B., DAWBER T. R., FRIEDMAN G. D., GLENNON W. E., MCNAMARA P. M. RISK FACTORS IN CORONARY HEART DISEASE. AN EVALUATION OF SEVERAL SERUM LIPIDS AS PREDICTORS OF CORONARY HEART DISEASE; THE FRAMINGHAM STUDY. Ann Intern Med. 1964 Nov;61:888–899. doi: 10.7326/0003-4819-61-5-888. [DOI] [PubMed] [Google Scholar]
  18. Kannel W. B., Doyle J. T., McNamara P. M., Quickenton P., Gordon T. Precursors of sudden coronary death. Factors related to the incidence of sudden death. Circulation. 1975 Apr;51(4):606–613. doi: 10.1161/01.cir.51.4.606. [DOI] [PubMed] [Google Scholar]
  19. Keys A., Aravanis C., Blackburn H., Van Buchem F. S., Buzina R., Djordjevic B. S., Fidanza F., Karvonen M. J., Menotti A., Puddu V. Probability of middle-aged men developing coronary heart disease in five years. Circulation. 1972 Apr;45(4):815–828. doi: 10.1161/01.cir.45.4.815. [DOI] [PubMed] [Google Scholar]
  20. Krasno L. R., Kidera G. J. Clofibrate in coronary heart disease. Effect on morbidity and mortality. JAMA. 1972 Feb 14;219(7):845–851. [PubMed] [Google Scholar]
  21. Lithell H., Boberg J., Hedstrand H., Hellsing K., Ljunghall S., Vessby B. Effects of clofibrate on glucose tolerance, serum insulin, serum lipoproteins and plasma fibrinogen. Eur J Clin Pharmacol. 1977 Aug 17;12(1):51–57. doi: 10.1007/BF00561405. [DOI] [PubMed] [Google Scholar]
  22. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966 Mar;50(3):163–170. [PubMed] [Google Scholar]
  23. Medalie J. H., Kahn H. A., Neufeld H. N., Riss E., Goldbourt U., Perlstein T., Oron D. Myocardial infarction over a five-year period. I. Prevalence, incidence and mortality experience. J Chronic Dis. 1973 Feb;26(2):63–84. doi: 10.1016/0021-9681(73)90006-4. [DOI] [PubMed] [Google Scholar]
  24. Miettinen M., Turpeinen O., Karvonen M. J., Elosuo R., Paavilainen E. Effect of cholesterol-lowering diet on mortality from coronary heart-disease and other causes. A twelve-year clinical trial in men and women. Lancet. 1972 Oct 21;2(7782):835–838. doi: 10.1016/s0140-6736(72)92208-8. [DOI] [PubMed] [Google Scholar]
  25. OLIVER M. F. Reduction of serum-lipid and uric-acid levels by an orally active androsterone. Lancet. 1962 Jun 23;1(7243):1321–1323. doi: 10.1016/s0140-6736(62)92422-4. [DOI] [PubMed] [Google Scholar]
  26. Pertsemlidis D., Panveliwalla D., Ahrens E. H., Jr Effects of clofibrate and of an estrogen-progestin combination on fasting biliary lipids and cholic acid kinetics in man. Gastroenterology. 1974 Apr;66(4):565–573. [PubMed] [Google Scholar]
  27. Sturdevant R. A., Pearce M. L., Dayton S. Increased prevalence of cholelithiasis in men ingesting a serum-cholesterol-lowering diet. N Engl J Med. 1973 Jan 4;288(1):24–27. doi: 10.1056/NEJM197301042880106. [DOI] [PubMed] [Google Scholar]
  28. THORP J. M., WARING W. S. Modification of metabolism and distribution of lipids by ethyl chlorophenoxyisobutyrate. Nature. 1962 Jun 9;194:948–949. doi: 10.1038/194948a0. [DOI] [PubMed] [Google Scholar]
  29. THROP J. M. Experimental evaluation of an orally active combination of androsterone with ethyl chlorophenoxy-isobutyrate. Lancet. 1962 Jun 23;1(7243):1323–1326. doi: 10.1016/s0140-6736(62)92423-6. [DOI] [PubMed] [Google Scholar]
  30. Walker S. H., Duncan D. B. Estimation of the probability of an event as a function of several independent variables. Biometrika. 1967 Jun;54(1):167–179. [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES